Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 11
2022
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
2,500
-6.11%
|
$67,500
$27.4 P/Share
|
|
Jan 11
2022
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
5,000
-11.75%
|
$135,000
$27.4 P/Share
|
|
Jan 10
2022
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.19%
|
-
|
|
Jan 10
2022
|
William E. Rote Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.89%
|
-
|
|
Jan 10
2022
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+10.52%
|
-
|
|
Jan 05
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-4.16%
|
$375,000
$30.16 P/Share
|
|
Jan 04
2022
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,832
-3.08%
|
$144,960
$30.43 P/Share
|
|
Jan 01
2022
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Nov 16
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
31,800
-17.54%
|
$922,200
$29.39 P/Share
|
|
Nov 05
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.82%
|
$260,000
$26.23 P/Share
|
|
Nov 05
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.5%
|
$160,000
$16.23 P/Share
|
|
Nov 02
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Indirect |
3,500
-15.22%
|
$105,000
$30.0 P/Share
|
|
Nov 01
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Indirect |
5,000
-17.86%
|
$145,000
$29.48 P/Share
|
|
Oct 07
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
60,000
-12.82%
|
$1,560,000
$26.25 P/Share
|
|
Oct 07
2021
|
Steve Aselage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+19.37%
|
$960,000
$16.23 P/Share
|
|
Oct 04
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,058
-4.81%
|
$73,392
$24.77 P/Share
|
|
Sep 14
2021
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
Aug 17
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,407
-4.3%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
1,407
-3.61%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,407
-3.79%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.87%
|
$23,919
$17.12 P/Share
|
|
Aug 17
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,836
-4.76%
|
$133,212
$17.12 P/Share
|
|
Aug 17
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,407
-2.17%
|
$23,919
$17.12 P/Share
|
|
Aug 13
2021
|
Laura Clague Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.09%
|
-
|
|
Aug 13
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.36%
|
-
|
|
Aug 13
2021
|
William E. Rote Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+10.81%
|
-
|
|
Aug 13
2021
|
Noah L. Rosenberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+8.41%
|
-
|
|
Aug 13
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+9.6%
|
-
|
|
Aug 13
2021
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+6.48%
|
-
|
|
Jul 28
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,250
-2.73%
|
$16,250
$13.81 P/Share
|
|
Jul 16
2021
|
Steve Aselage Director |
BUY
Bona fide gift
|
Indirect |
3,000
+9.68%
|
-
|
|
Jul 16
2021
|
Steve Aselage Director |
SELL
Bona fide gift
|
Direct |
3,000
-1.82%
|
-
|
|
Jun 02
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,780
-3.14%
|
$66,920
$14.35 P/Share
|
|
Jun 01
2021
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,782
-3.05%
|
$66,948
$14.89 P/Share
|
|
May 14
2021
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.78%
|
-
|
|
May 14
2021
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+24.0%
|
-
|
|
May 14
2021
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.78%
|
-
|
|
May 14
2021
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+4.29%
|
-
|
|
May 14
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+1.56%
|
-
|
|
May 14
2021
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.5%
|
-
|
|
May 14
2021
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+15.0%
|
-
|
|
May 14
2021
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+26.67%
|
-
|
|
May 14
2021
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+7.89%
|
-
|
|
May 12
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-6.62%
|
$38,000
$19.46 P/Share
|
|
May 12
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
1,625
-4.5%
|
$30,875
$19.46 P/Share
|
|
May 12
2021
|
Noah L. Rosenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.82%
|
$7,125
$19.46 P/Share
|
|
May 12
2021
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,562
-4.7%
|
$29,678
$19.46 P/Share
|
|
May 11
2021
|
Steve Aselage Director |
SELL
Open market or private sale
|
Direct |
2,146
-1.14%
|
$40,774
$19.58 P/Share
|
|
May 11
2021
|
Laura Clague Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-6.21%
|
$38,000
$19.14 P/Share
|
|
May 11
2021
|
Elizabeth E Reed Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
1,625
-4.31%
|
$30,875
$19.14 P/Share
|